Li Ya-jie, Li Yong-wang, Ding Xu, Zhao Hong-tao, Li Ying
The Second Comprehensive Department, Dalian Municipal Central Hospital, Dalian 116033, China.
Zhonghua Yu Fang Yi Xue Za Zhi. 2010 Sep;44(9):820-4.
To evaluate the associations between polymorphisms of methionine synthase(MTR) A2756G and methionine synthase reductase(MTRR) G66A and risk of coronary artery disease.
Literatures in Medline reporting the relationship between polymorphisms of MTR A2756G and MTRR G66A and risk of coronary artery disease from January 1990 to May 2010 were searched. A total of 14 relevant articles were selected and 13 of them met the criteria. A Meta-analysis was performed to estimate the pooled odds ratio (OR) to evaluate the relationship between polymorphisms of MTR A2756G and MTRR G66A and risk of coronary artery disease. All analyses were performed using the STATA statistical software.
Among the 13 studies, eight case-control studies containing 2143 cases of coronary artery disease and 2270 controls were included in the analysis of MTR A2756G and risk of coronary artery disease. Meanwhile, five case-control studies with 811 cases of coronary artery disease and 387 controls were included in the analysis of MTRR G66A and risk of coronary artery disease. In the analysis of MTRR G66A related to the risk of coronary artery disease, there were 246 GG carries, 397 AG carriers and 168 AA carriers in the group of coronary artery disease, against 102 GG carriers, 203 AG carriers and 82 AA carriers in the control group. Compared with the MTRR GG carriers, the risk of coronary artery disease decreased significantly by 27% (OR = 0.73, 95%CI: 0.54 - 0.99) and 25% (OR = 0.75, 95%CI: 0.56 - 1.00) (Egger's test t = -0.19, P = 0.862) in the MTRR 66 AG and AG/AA carriers, respectively, and also decreased in the MTRR AA carriers but significant difference was observed (OR = 0.84, 95%CI: 0.42 - 1.68). There was no significant association between coronary artery disease and MTR A2756G.
These results suggest that MTRR66 may play a role in coronary artery disease susceptibility. MTRR 66 A allele carries are associated with a statistically significant decreased risk of coronary artery disease susceptibility.
评估甲硫氨酸合成酶(MTR)A2756G多态性和甲硫氨酸合成酶还原酶(MTRR)G66A多态性与冠状动脉疾病风险之间的关联。
检索1990年1月至2010年5月期间Medline中报道MTR A2756G和MTRR G66A多态性与冠状动脉疾病风险关系的文献。共筛选出14篇相关文章,其中13篇符合标准。进行Meta分析以估计合并比值比(OR),评估MTR A2756G和MTRR G66A多态性与冠状动脉疾病风险之间的关系。所有分析均使用STATA统计软件进行。
在这13项研究中,8项病例对照研究(包含2143例冠状动脉疾病患者和2270例对照)纳入了MTR A2756G与冠状动脉疾病风险的分析。同时,5项病例对照研究(有811例冠状动脉疾病患者和387例对照)纳入了MTRR G66A与冠状动脉疾病风险的分析。在与冠状动脉疾病风险相关的MTRR G66A分析中,冠状动脉疾病组中有246例GG携带者、397例AG携带者和168例AA携带者,对照组中有102例GG携带者、203例AG携带者和82例AA携带者。与MTRR GG携带者相比,MTRR 66 AG和AG/AA携带者患冠状动脉疾病的风险分别显著降低27%(OR = 0.73,95%CI:0.54 - 0.99)和25%(OR = 0.75,95%CI:0.56 - 1.00)(Egger检验t = -0.19,P = 0.862),MTRR AA携带者的风险也降低,但差异无统计学意义(OR = 0.84,95%CI:0.42 - 1.68)。冠状动脉疾病与MTR A2756G之间无显著关联。
这些结果表明MTRR66可能在冠状动脉疾病易感性中起作用。MTRR 66 A等位基因携带者患冠状动脉疾病易感性的风险在统计学上显著降低。